GLP-1 receptor agonists mimic a gut hormone released after eating. They prompt the pancreas to release insulin when blood sugar is high, slow how quickly the stomach empties, and act on the brain to reduce appetite. Developed for type-2 diabetes, they turned out to cause substantial weight loss — which is why they have become the most talked-about medicines of the decade. Tirzepatide goes further, activating the GIP receptor as well as GLP-1.
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
Plain-English summaries and drug-class explainers are written and reviewed by the Priya Life Science editorial team, led by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 28 Aug 2026.